1887

Journal of General Virology header logo

Volume 105, Issue 3

Structural basis for nuclear import of bat adeno-associated virus capsid protein Open Access

Abstract

Adeno-associated viruses (AAV) are one of the world’s most promising gene therapy vectors and as a result, are one of the most intensively studied viral vectors. Despite a wealth of research into these vectors, the precise characterisation of AAVs to translocate into the host cell nucleus remains unclear. Recently we identified the nuclear localization signals of an AAV porcine strain and determined its mechanism of binding to host importin proteins. To expand our understanding of diverse AAV import mechanisms we sought to determine the mechanism in which the Cap protein from a bat-infecting AAV can interact with transport receptor importins for translocation into the nucleus. Using a high-resolution crystal structure and quantitative assays, we were able to not only determine the exact region and residues of the N-terminal domain of the Cap protein which constitute the functional NLS for binding with the importin alpha two protein, but also reveal the differences in binding affinity across the importin-alpha isoforms. Collectively our results allow for a detailed molecular view of the way AAV Cap proteins interact with host proteins for localization into the cell nucleus.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): adeno-associated virus , importin , karyopherin and nuclear import
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001960
2024-03-05
2024-04-27
Loading full text...

Full text loading...

/deliver/fulltext/jgv/105/3/jgv001960.html?itemId=/content/journal/jgv/10.1099/jgv.0.001960&mimeType=html&fmt=ahah

References

  1. Cotmore SF, Agbandje-McKenna M, Canuti M, Chiorini JA, Eis-Hubinger A-M et al. ICTV virus taxonomy profile: Parvoviridae. J Gen Virol 2019; 100:367–368 [View Article] [PubMed]
     [Google Scholar]
  2. Cotmore SF, Agbandje-McKenna M, Chiorini JA, Mukha DV, Pintel DJ et al. The family Parvoviridae. Arch Virol 2014; 159:1239–1247 [View Article] [PubMed]
     [Google Scholar]
  3. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 2019; 18:358–378 [View Article] [PubMed]
     [Google Scholar]
  4. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14:316–327 [View Article] [PubMed]
     [Google Scholar]
  5. Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 2020; 21:255–272 [View Article] [PubMed]
     [Google Scholar]
  6. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010; 21:704–712 [View Article] [PubMed]
     [Google Scholar]
  7. Smith RH. Adeno-associated virus integration: virus versus vector. Gene Ther 2008; 15:817–822 [View Article] [PubMed]
     [Google Scholar]
  8. Berns K, Parrish CR. Parvoviridae. In Knipe DM, Howley PM. eds Fields Virology Philadelphia, PA, USA: Wolters Kluwer Health; 2013 pp 1768–1791
     [Google Scholar]
  9. Atchison RW. The role of herpesviruses in adenovirus-associated virus replication in vitro. Virology 1970; 42:155–162 [View Article] [PubMed]
     [Google Scholar]
  10. Ogston P, Raj K, Beard P. Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein. J Virol 2000; 74:3494–3504 [View Article] [PubMed]
     [Google Scholar]
  11. Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T et al. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 2005; 79:609–614 [View Article] [PubMed]
     [Google Scholar]
  12. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16:1073–1080 [View Article] [PubMed]
     [Google Scholar]
  13. Davidsson M, Wang G, Aldrin-Kirk P, Cardoso T, Nolbrant S et al. A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism. Proc Natl Acad Sci U S A 2019; 116:27053–27062 [View Article] [PubMed]
     [Google Scholar]
  14. Lee EJ, Guenther CM, Suh J. Adeno-Associated Virus (AAV) vectors: rational design strategies for capsid engineering. Curr Opin Biomed Eng 2018; 7:58–63 [View Article] [PubMed]
     [Google Scholar]
  15. Asokan A, Conway JC, Phillips JL, Li C, Hegge J et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 2010; 28:79–82 [View Article] [PubMed]
     [Google Scholar]
  16. Bernaud J, Rossi A, Fis A, Gardette L, Aillot L et al. Characterization of AAV vector particle stability at the single-capsid level. J Biol Phys 2018; 44:181–194 [View Article] [PubMed]
     [Google Scholar]
  17. Au HKE, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med 2021; 8:809118 [View Article] [PubMed]
     [Google Scholar]
  18. Chowdhury EA, Meno-Tetang G, Chang HY, Wu S, Huang HW et al. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models. Adv Drug Deliv Rev 2021; 170:214–237 [View Article] [PubMed]
     [Google Scholar]
  19. Khan IF, Hirata RK, Wang P-R, Li Y, Kho J et al. Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther 2010; 18:1192–1199 [View Article] [PubMed]
     [Google Scholar]
  20. Brown N, Song L, Kollu NR, Hirsch ML. Adeno-associated virus vectors and stem cells: friends or foes?. Hum Gene Ther 2017; 28:450–463 [View Article] [PubMed]
     [Google Scholar]
  21. Batty P, Lillicrap D. Advances and challenges for hemophilia gene therapy. Hum Mol Genet 2019; 28:R95–R101 [View Article] [PubMed]
     [Google Scholar]
  22. Johnson TB, White KA, Brudvig JJ, Cain JT, Langin L et al. AAV9 gene therapy increases lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-batten disease. Mol Ther 2021; 29:162–175 [View Article] [PubMed]
     [Google Scholar]
  23. Lu Y, Brommer B, Tian X, Krishnan A, Meer M et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature 2020; 588:124–129 [View Article] [PubMed]
     [Google Scholar]
  24. Martinez-Navio JM, Fuchs SP, Pantry SN, Lauer WA, Duggan NN et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 2019; 50:567–575 [View Article] [PubMed]
     [Google Scholar]
  25. Zhu D, Schieferecke AJ, Lopez PA, Schaffer DV. Adeno-associated virus vector for central nervous system gene therapy. Trends Mol Med 2021; 27:524–537 [View Article] [PubMed]
     [Google Scholar]
  26. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199:381–390 [View Article] [PubMed]
     [Google Scholar]
  27. Liu Q, Huang W, Zhang H, Wang Y, Zhao J et al. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther 2014; 21:732–738 [View Article] [PubMed]
     [Google Scholar]
  28. Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods 2013; 24:59–67 [View Article] [PubMed]
     [Google Scholar]
  29. Arbetman AE, Lochrie M, Zhou S, Wellman J, Scallan C et al. Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J Virol 2005; 79:15238–15245 [View Article] [PubMed]
     [Google Scholar]
  30. De BP, Heguy A, Hackett NR, Ferris B, Leopold PL et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther 2006; 13:67–76 [View Article] [PubMed]
     [Google Scholar]
  31. Schmidt M, Katano H, Bossis I, Chiorini JA. Cloning and characterization of a bovine adeno-associated virus. J Virol 2004; 78:6509–6516 [View Article] [PubMed]
     [Google Scholar]
  32. Li Y, Li J, Liu Y, Shi Z, Liu H et al. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies. Gene Ther 2019; 26:264–276 [View Article]
     [Google Scholar]
  33. Horowitz ED, Rahman KS, Bower BD, Dismuke DJ, Falvo MR et al. Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. J Virol 2013; 87:2994–3002 [View Article] [PubMed]
     [Google Scholar]
  34. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 2006; 80:11040–11054 [View Article] [PubMed]
     [Google Scholar]
  35. Lu J, Wu T, Zhang B, Liu S, Song W et al. Types of nuclear localization signals and mechanisms of protein import into the nucleus. Cell Commun Signal 2021; 19:60 [View Article] [PubMed]
     [Google Scholar]
  36. Goldfarb DS, Corbett AH, Mason DA, Harreman MT, Adam SA. Importin alpha: a multipurpose nuclear-transport receptor. Trends Cell Biol 2004; 14:505–514 [View Article] [PubMed]
     [Google Scholar]
  37. Cingolani G, Petosa C, Weis K, Müller CW. Structure of importin-beta bound to the IBB domain of importin-alpha. Nature 1999; 399:221–229 [View Article] [PubMed]
     [Google Scholar]
  38. Kelley JB, Talley AM, Spencer A, Gioeli D, Paschal BM. Karyopherin alpha7 (KPNA7), a divergent member of the importin alpha family of nuclear import receptors. BMC Cell Biol 2010; 11:63 [View Article] [PubMed]
     [Google Scholar]
  39. Wing CE, Fung HYJ, Chook YM. Karyopherin-mediated nucleocytoplasmic transport. Nat Rev Mol Cell Biol 2022; 23:307–328 [View Article] [PubMed]
     [Google Scholar]
  40. Lee SJ, Matsuura Y, Liu SM, Stewart M. Structural basis for nuclear import complex dissociation by RanGTP. Nature 2005; 435:693–696 [View Article] [PubMed]
     [Google Scholar]
  41. Milles S, Mercadante D, Aramburu IV, Jensen MR, Banterle N et al. Plasticity of an ultrafast interaction between nucleoporins and nuclear transport receptors. Cell 2015; 163:734–745 [View Article] [PubMed]
     [Google Scholar]
  42. Grieger JC, Snowdy S, Samulski RJ. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J Virol 2006; 80:5199–5210 [View Article] [PubMed]
     [Google Scholar]
  43. Hoad M, Roby JA, Forwood JK. Structural characterization of the porcine adeno-associated virus Po1 capsid protein binding to the nuclear trafficking protein importin alpha. FEBS Lett 2021; 595:2793–2804 [View Article] [PubMed]
     [Google Scholar]
  44. Nicolson SC, Samulski RJ. Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol 2014; 88:4132–4144 [View Article] [PubMed]
     [Google Scholar]
  45. Hoad M, Cross EM, Donnelly CM, Sarker S, Roby JA et al. Structural characterization of porcine adeno-associated virus capsid protein with nuclear trafficking protein importin alpha reveals a bipartite nuclear localization signal. Viruses 2023; 15:315 [View Article] [PubMed]
     [Google Scholar]
  46. Becerra SP, Rose JA, Hardy M, Baroudy BM, Anderson CW. Direct mapping of adeno-associated virus capsid proteins B and C: a possible ACG initiation codon. Proc Natl Acad Sci U S A 1985; 82:7919–7923 [View Article] [PubMed]
     [Google Scholar]
  47. Jay FT, Laughlin CA, Carter BJ. Eukaryotic translational control: adeno-associated virus protein synthesis is affected by a mutation in the adenovirus DNA-binding protein. Proc Natl Acad Sci U S A 1981; 78:2927–2931 [View Article] [PubMed]
     [Google Scholar]
  48. Muralidhar S, Becerra SP, Rose JA. Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity. J Virol 1994; 68:170–176 [View Article] [PubMed]
     [Google Scholar]
  49. Trempe JP, Carter BJ. Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein. J Virol 1988; 62:3356–3363 [View Article] [PubMed]
     [Google Scholar]
  50. Becerra SP, Koczot F, Fabisch P, Rose JA. Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J Virol 1988; 62:2745–2754 [View Article] [PubMed]
     [Google Scholar]
  51. Bennett A, Mietzsch M, Agbandje-McKenna M. Understanding capsid assembly and genome packaging for adeno-associated viruses. Future Virol 2017; 12:283–297 [View Article] [PubMed]
     [Google Scholar]
  52. Wörner TP, Bennett A, Habka S, Snijder J, Friese O et al. Adeno-associated virus capsid assembly is divergent and stochastic. Nat Commun 2021; 12:1642 [View Article] [PubMed]
     [Google Scholar]
  53. Govindasamy L, Padron E, McKenna R, Muzyczka N, Kaludov N et al. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol 2006; 80:11556–11570 [View Article] [PubMed]
     [Google Scholar]
  54. Padron E, Bowman V, Kaludov N, Govindasamy L, Levy H et al. Structure of adeno-associated virus type 4. J Virol 2005; 79:5047–5058 [View Article] [PubMed]
     [Google Scholar]
  55. Mietzsch M, Pénzes JJ, Agbandje-McKenna M. Twenty-five years of structural parvovirology. Viruses 2019; 11:362 [View Article] [PubMed]
     [Google Scholar]
  56. Kronenberg S, Böttcher B, von der Lieth CW, Bleker S, Kleinschmidt JA. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol 2005; 79:5296–5303 [View Article] [PubMed]
     [Google Scholar]
  57. Kronenberg S, Kleinschmidt JA, Böttcher B. Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep 2001; 2:997–1002 [View Article] [PubMed]
     [Google Scholar]
  58. Bleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J Virol 2005; 79:2528–2540 [View Article] [PubMed]
     [Google Scholar]
  59. Grieger JC, Johnson JS, Gurda-Whitaker B, Agbandje-McKenna M, Samulski RJ. Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions. J Virol 2007; 81:7833–7843 [View Article] [PubMed]
     [Google Scholar]
  60. Popa-Wagner R, Porwal M, Kann M, Reuss M, Weimer M et al. Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol 2012; 86:9163–9174 [View Article] [PubMed]
     [Google Scholar]
  61. Stahnke S, Lux K, Uhrig S, Kreppel F, Hösel M et al. Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology 2011; 409:77–83 [View Article] [PubMed]
     [Google Scholar]
  62. Venkatakrishnan B, Yarbrough J, Domsic J, Bennett A, Bothner B et al. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol 2013; 87:4974–4984 [View Article] [PubMed]
     [Google Scholar]
  63. Popa-Wagner R, Sonntag F, Schmidt K, King J, Kleinschmidt JA. Nuclear translocation of adeno-associated virus type 2 capsid proteins for virion assembly. J Gen Virol 2012; 93:1887–1898 [View Article]
     [Google Scholar]
  64. Johnson JS, Li C, DiPrimio N, Weinberg MS, McCown TJ et al. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 2010; 84:8888–8902 [View Article] [PubMed]
     [Google Scholar]
  65. Teh T, Tiganis T, Kobe B. Crystallization of importin alpha, the nuclear-import receptor. Acta Crystallogr D Biol Crystallogr 1999; 55:561–563 [View Article] [PubMed]
     [Google Scholar]
  66. Munasinghe TS, Edwards MR, Tsimbalyuk S, Vogel OA, Smith KM et al. MERS-CoV ORF4b employs an unusual binding mechanism to target IMPα and block innate immunity. Nat Commun 2022; 13:1604 [View Article] [PubMed]
     [Google Scholar]
  67. Roman N, Christie M, Swarbrick CMD, Kobe B, Forwood JK. Structural characterisation of the nuclear import receptor importin alpha in complex with the bipartite NLS of Prp20. PLoS One 2013; 8:e82038 [View Article] [PubMed]
     [Google Scholar]
  68. Studier FW. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 2005; 41:207–234 [View Article] [PubMed]
     [Google Scholar]
  69. McPhillips TM, McPhillips SE, Chiu H-J, Cohen AE, Deacon AM et al. Blu-ice and the distributed control system: software for data acquisition and instrument control at macromolecular crystallography beamlines. J Synchrotron Radiat 2002; 9:401–406 [View Article] [PubMed]
     [Google Scholar]
  70. Battye TGG, Kontogiannis L, Johnson O, Powell HR, Leslie AGW. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 2011; 67:271–281 [View Article] [PubMed]
     [Google Scholar]
  71. Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 2006; 62:72–82 [View Article] [PubMed]
     [Google Scholar]
  72. Evans PR. An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr D Biol Crystallogr 2011; 67:282–292 [View Article] [PubMed]
     [Google Scholar]
  73. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC et al. Phaser crystallographic software. J Appl Crystallogr 2007; 40:658–674 [View Article] [PubMed]
     [Google Scholar]
  74. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126–2132 [View Article] [PubMed]
     [Google Scholar]
  75. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010; 66:486–501 [View Article] [PubMed]
     [Google Scholar]
  76. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 2011; 67:235–242 [View Article] [PubMed]
     [Google Scholar]
  77. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW et al. PHENIX:a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010; 66:213–221 [View Article]
     [Google Scholar]
  78. Kobe B. Autoinhibition by an internal nuclear localization signal revealed by the crystal structure of mammalian importin alpha. Nat Struct Biol 1999; 6:388–397 [View Article]
     [Google Scholar]
  79. Fontes MRM, Teh T, Jans D, Brinkworth RI, Kobe B. Structural basis for the specificity of bipartite nuclear localization sequence binding by importin-alpha. J Biol Chem 2003; 278:27981–27987 [View Article] [PubMed]
     [Google Scholar]
  80. Marfori M, Lonhienne TG, Forwood JK, Kobe B. Structural basis of high-affinity nuclear localization signal interactions with importin-α. Traffic 2012; 13:532–548 [View Article] [PubMed]
     [Google Scholar]
  81. Tarendeau F, Boudet J, Guilligay D, Mas PJ, Bougault CM et al. Structure and nuclear import function of the C-terminal domain of influenza virus polymerase PB2 subunit. Nat Struct Mol Biol 2007; 14:229–233 [View Article] [PubMed]
     [Google Scholar]
  82. Pumroy RA, Ke S, Hart DJ, Zachariae U, Cingolani G. Molecular determinants for nuclear import of influenza A PB2 by importin α isoforms 3 and 7. Structure 2015; 23:374–384 [View Article] [PubMed]
     [Google Scholar]
  83. Sankhala RS, Lokareddy RK, Begum S, Pumroy RA, Gillilan RE et al. Three-dimensional context rather than NLS amino acid sequence determines importin α subtype specificity for RCC1. Nat Commun 2017; 8:979 [View Article]
     [Google Scholar]
  84. Smith KM, Tsimbalyuk S, Edwards MR, Cross EM, Batra J et al. Structural basis for importin alpha 3 specificity of W proteins in Hendra and Nipah viruses. Nat Commun 2018; 9:3703 [View Article] [PubMed]
     [Google Scholar]
  85. Tsimbalyuk S, Donnelly CM, Forwood JK. Structural characterization of human importin alpha 7 in its cargo-free form at 2.5 Å resolution. Sci Rep 2022; 12:315 [View Article] [PubMed]
     [Google Scholar]
  86. Fontes MR, Teh T, Kobe B. Structural basis of recognition of monopartite and bipartite nuclear localization sequences by mammalian importin-alpha. J Mol Biol 2000; 297:1183–1194 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001960
Loading
Structural basis for nuclear import of bat adeno-associated virus capsid protein
J. Gen. Virol. 105, 001960 (2024); https://doi.org/10.1099/jgv.0.001960
/content/journal/jgv/10.1099/jgv.0.001960
/content/journal/jgv/10.1099/jgv.0.001960
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error